Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control throughout protocol treatment
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment
Men and women of childbearing potential must be willing to practice an effective method of birth control during treatment and at least 4 months after treatment is finished
Male and female subjects of childbearing potential must agree to use an effective means of birth control to avoid pregnancy throughout the transplant procedure, while on immunosuppression, and if the subject experiences any chronic GvHD
Women of childbearing potential are willing to agree to use 1 of the study-defined effective methods of birth control from the time of study entry to 6 months after the last day of treatment
Men and women of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study through 1 week (women) or 12 weeks (men)
Women of childbearing potential are willing to agree to use 1 of the study defined effective methods of birth control from the time of study entry to 6 months after the last day of treatment
Women of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with CC-486 or nab-paclitaxel; all men and women of childbearing potential must use effective methods of birth control throughout the study and for three months after completing treatment
Inability or refusal to practice effective contraception during therapy; men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for 4 months after completion of the treatment
Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment
Women of childbearing potential must use an acceptable form of birth control for 28 days prior to beginning study treatment, through the duration of study treatment, and for 3 months after discontinuing study treatment
Subjects of reproductive potential who are not willing to employ effective birth control from screening to 1 year after last dose of vaccine
Subjects of reproductive potential who do not use effective methods of birth control
Men and women of childbearing potential must practice birth control; women of child bearing potential must have a urine pregnancy test within 7 days of study entry; in accordance with topotecan hydrochloride (topotecan) administration guidelines, women must practice birth control for at least 1 month following chemotherapy infusion; men must practice birth control for at least four months following termination of chemotherapy infusion
Men and women of childbearing potential must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for 3 months after therapy completed
All sexually active subjects of reproductive potential are required to use or start using a reliable method of birth control at least 2 weeks prior to study enrollment, throughout the study, and for at least 3 months following completion of study therapy.
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
Women of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study and until 12 months following the last study treatment.
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment
Subjects of reproductive potential must agree to use acceptable birth control methods
Women and men of reproductive potential who are unwilling or unable to use an effective means of birth control during the study and for 3 months after receiving study drug
Subjects of reproductive potential must agree to use acceptable birth control methods
Subjects of reproductive potential must agree to use acceptable birth control methods
Subjects of reproductive potential must agree to use acceptable birth control methods
Subjects of reproductive potential must agree to use acceptable birth control methods
Women who are breast feeding, or have a positive pregnancy test (reproductive age should use effective birth control during study if randomized to SBRT treatment arm)
Men and women of childbearing potential must be willing to practice an effective method of birth control during treatment and for at least 4 months following treatment on study
Women of childbearing potential and men must agree to use a medically accepted form of birth control during the treatment and for 2 months following completion of study treatment
Pregnant and nursing women should be excluded from the protocol; if the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy; it is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study
Women of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study participation and for 2 months following completion of study treatment
Women of childbearing potential must agree to practice effective birth control throughout their participation in the treatment phase of the study
Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment
Women who are pregnant (confirmed by a serum pregnancy test in females of reproductive potential) or breast-feeding; women of child-bearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment (unless the subject or subjectâ€™s partner(s) is sterile (i.e. women who have had a hysterectomy or have been post-menopausal for at least twelve consecutive months) or remain abstinent, men and women of reproductive potential must agree to use TWO of the following forms of birth control every time they have sex throughout the study and for up to 3 months following discontinuation of study drug: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicidal, intrauterine device (IUD), or surgical sterilization while participating in this study; hormonal birth control methods are not permitted
Women of child-bearing potential will practice a highly effective method of birth control during and for 3 months after the chemotherapy/ custirsen last dose. Men of reproductive potential who are not surgically sterile must agree to abstain from sexual activity or use medically accepted and highly effective method of contraception during and for 6 months after the chemotherapy/custirsen last dose.
Men and women of reproductive potential who are unwilling to practice acceptable methods of effective birth control while on study through 5 weeks (women) or 3 months (men) after receiving the last dose of AMG 232; acceptable methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or IUD (women)
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
Pregnant and/or lactating women will be excluded; premenopausal patients will undergo pregnancy testing when indicated; women will practice effective birth control while receiving protocol treatment
Any women who are pregnant or breast feeding, or women/men able to conceive and unwilling to practice an effective method of birth control
Non pregnant and non-nursing; treatment under this protocol would expose a fetus to significant risks; women of childbearing potential should have a negative pregnancy test prior to study entry; women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial; appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (Norplant), or double barrier method (diaphragm plus condom)
Women of childbearing potential and fertile men who are not practicing or who are\n             unwilling to practice birth control while enrolled in the study until at least 12\n             weeks after the last milatuzumab infusion
Women of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study
Pregnant and lactating women are excluded from this study; women of reproductive potential that are not using or are unwilling to use effective birth control methods throughout the trial are excluded
Men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control
Men and women with reproductive potential: Must agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug(s) or country requirements, whichever is longer.
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
All men and women of childbearing potential who are participating in the study must agree to use effective forms of birth control throughout the duration of their treatment
Men and women of reproductive potential who are unwilling to practice acceptable methods of effective birth control while on study through 5 weeks (women) or 3 months (men) after receiving the last dose of AMG 232; acceptable methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women)
Women of childbearing potential must agree to use highly effective methods of birth control.
Women and men of reproductive potential should agree to use two effective means of birth control\r\n* For women, contraception should continue for 23 weeks after the last dose of nivolumab and 12 weeks after the last dose of dasatinib to allow complete clearance of drug and its principal metabolites from the body\r\n* For men, contraception should continue for 31 weeks after nivolumab and 12 weeks after dasatinib
Women of childbearing potential (WOCBP) must practice 2 effective methods of birth control during the course of the study; male patients who are partners of WOCBP should also practice an effective method of contraception; effective methods of birth control include diaphragm or condoms with spermicidal foam or jelly, birth control pills (BCPs), injections or patches, intra-uterine devices (IUDs) and surgical sterilization; postmenopausal women must be amenorrheic for >= 12 months to be considered of non-childbearing potential, women and men must continue birth control for the duration of the trial and >= 3 months after the last dose of study drug, All WOCBP MUST have a negative pregnancy test prior to beginning ibrutinib on study
Male and female patients of reproductive potential must agree follow accepted birth control measures
Note: Women with potential to have children must be willing to practice acceptable methods of birth control during the study
Women of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment
Inability or refusal to practice effective contraception during therapy or the presence of pregnancy or active breastfeeding (men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for 4 months after completion of treatment)
Women of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with 5-azacitidine; all men and women of childbearing potential must use acceptable methods of birth control throughout the study
Non-pregnant and non-nursing; pregnant or nursing patients may not be enrolled; women and men of reproductive potential should agree to use an effective means of birth control
Non-pregnant and non-nursing; women and men of reproductive potential should agree to use an effective means of birth control
Females who are pregnant or breast-feeding during the study period will be excluded; adults of reproductive potential not employing an effective method of birth control will be excluded; sexually active women of child bearing potential, whose partner is male, must use medically accepted birth control; sexually active men, whose partner is a female of childbearing potential, must use a medically accepted birth control
Subjects of reproductive potential agree to use birth control throughout their participation in this study, and for three months following study termination.
Men and women with reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment
Women of childbearing potential and men with reproductive potential must be willing to continue practicing acceptable methods of birth control during the study NOTE: Oral contraceptives are not reliable due to potential drug-drug interaction with GSK2118436
Non-pregnant and non-nursing; women and men of reproductive potential should agree to use an effective means of birth control
Patients (men and women) of childbearing potential must use effective method of birth control throughout their participation in this study
Patients must not be pregnant; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatment
Women of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study participation and for 4 months following completion of study treatment
Pregnant and lactating women will be excluded; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatment
Women of childbearing potential must agree to practice effective birth control throughout their participation in the treatment phase of the study
All subjects of childbearing potential must agree to use acceptable methods of birth control (men and women)
Women of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatment
Women of childbearing potential and male participants must agree to practice adequate means of birth control throughout their participation in the study and for 6 months after their last treatment
Not pregnant or breast feeding; women of childbearing potential and sexually active men must agree to use an accepted and effective method of birth control
Women of childbearing potential or men with partners of childbearing potential who are not protected or who are unwilling to use an effective contraceptive method of birth control during the course of the study and for a period of 6 months following the last dose.
Pregnant and/or lactating women will be excluded; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatment
Men and woman of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and continuing for 2 weeks (for women) and 12 weeks (for men) after receiving the last dose of study drug.
Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication.
Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication.
Inability or refusal to practice effective contraception during therapy or the presence of pregnancy or active breastfeeding (men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for four months after completion of treatment)
Women with potential to have children must be willing to practice acceptable methods of birth control during the study;
Women and men agree to use protocol specific birth control measures
If female patient with reproductive capacity: on effective means of barrier birth control during the entire duration of the treatment
Pregnant women are ineligible, as treatment involves unforeseeable risks to the embryo or fetus; female patients with reproductive capacity are required to use effective means of birth control during the entire duration of the treatment
Women and men of reproductive potential must agree to use an effective means of birth control during the study and for 3 months after receiving study drug
Pregnant or breast feeding; women and men of reproductive potential must agree to use an effective means of birth control during the study and for 3 months after receiving study drug
For women of childbearing potential: unwillingness to use an effective method of birth control (e.g., abstinence, oral contraceptive) while in this study
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
Women and men must continue birth control for the duration of the trial and >= 3 months after the last dose of study drug
Participants of reproductive potential agree to remain abstinent, or use a medically accepted method of birth control
Subjects who are of reproductive potential who refuse to use effective methods of birth control during the course of participation of the study and within 5 month for women and 7 months for men of the last dose of investigational agent are ineligible to participate in the study.
Patients must not be pregnant; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatment
